Cargando…
Temozolomide abrogates the aggressiveness of urothelial carcinoma cells by enhancing senescence and depleting the side population
Patients with advanced urothelial carcinoma (UC) generally have poor prognoses due to therapeutic resistance. Furthermore, there are limited treatment options for advanced UC. Therefore, novel or effective chemotherapeutic agents are needed to improve patient survival. The present study was conducte...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561215/ https://www.ncbi.nlm.nih.gov/pubmed/34733363 http://dx.doi.org/10.3892/ol.2021.13106 |